Salivary Glucose Levels Measured by Biochip Sensor
|
By LabMedica International staff writers Posted on 18 Jun 2014 |

Image: The schematic shows glucose molecules sliding along the biochip sensor surface illuminated by different colors. Change in light intensity transmitted through the slits of each plasmonic interferometer can be used to measure the glucose concentration in saliva (Photo courtesy of Domenico Pacifici, PhD).
A new biochip sensor has been developed that can selectively measure concentrations of glucose in a complex solution similar to human saliva.
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
Latest Clinical Chem. News
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Channels
Molecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







